Physician profile
Chau Vu
NPI 1932636081
$8,489.35
in general payments reported to CMS, 2019-2025
36 companies · $1,634 in 2025
The $1,634 reported for 2025 was more than what 80% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $360 · 2020: $208 · 2021: $967 · 2022: $2,044 · 2023: $914 · 2024: $2,362 · 2025: $1,634.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,910.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,910.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $903.43 | 2021-2024 | Watchman Flx |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $782.51 | 2024-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $711.86 | 2022-2024 | Xarelto |
| Edwards Lifesciences Corporation | $653.68 | 2023-2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Amgen INC. | $594.87 | 2022-2025 | Repatha, Repatha |
| Abbott Laboratories | $462.17 | 2020-2024 | Cardiomems |
| Medtronic, INC. | $439.38 | 2021-2024 | Micra |
| Novartis Pharmaceuticals Corporation | $412.17 | 2023-2025 | |
| Pfizer INC. | $399.48 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $326.71 | 2023-2025 | Camzyos, Eliquis |
| W. L. Gore & Associates, INC. | $307.56 | 2022 | |
| Acist Medical Systems, INC. | $247.91 | 2022 | |
| Amarin Pharma, INC. | $225.68 | 2019 | |
| Cleerly, INC. | $180.34 | 2024 | Cleerly Labs, Cleerly Ischemia |
| Cardiovascular Systems INC. | $172.45 | 2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $161.14 | 2023-2024 | Optimizer, Optimizer |
| Alnylam Pharmaceuticals INC. | $145.23 | 2023-2025 | Amvuttra |
| Endologix LLC | $142.95 | 2021 | |
| Heartflow, INC. | $139.82 | 2024 | |
| Merck Sharp & Dohme LLC | $139.37 | 2023-2025 | Verquvo, Capvaxive |
| Philips North America LLC | $134.29 | 2021 | |
| Shockwave Medical, INC | $131.14 | 2021 | |
| Cook Medical LLC | $108.50 | 2021 | |
| Astellas Pharma US INC | $75.00 | 2021 | |
| Penumbra, INC. | $73.66 | 2022 | |
| Novo Nordisk INC | $64.07 | 2025 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.24 | 2024-2025 | Jardiance |
| Lilly USA, LLC | $51.79 | 2025 | Zepbound, Mounjaro |
| Actelion Pharmaceuticals US, INC. | $48.53 | 2024-2025 | Opsumit, Uptravi |
| Veryan Medical Incorporated | $48.33 | 2022 | |
| Angiodynamics, INC. | $48.25 | 2022 | |
| Kestra Medical Technology Services, INC. | $24.37 | 2023 | Assure Wcd |
| Endotronix, INC. | $21.39 | 2025 | Cordella Pulomonary Artery Pressure Sensor |
| Kiniksa Pharmaceuticals, LTD. | $20.16 | 2023 | Arcalyst |
| Sentynl Therapeutics, INC. | $19.93 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $16.99 | 2023 | Wainua |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chau Vu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.